Prevalence of cardiovascular risk factors in HIV-infected patients

被引:17
作者
Jerico, C. [1 ]
Knobel, H. [1 ]
Sorli, M. L. [1 ]
Montero, M. [1 ]
Guelar, A. [1 ]
Pedro-Botet, J. [1 ]
机构
[1] Univ Autonoma Barcelona, Serv Med Interna & Enfermedades Infecciosas, Hosp Mar, Barcelona, Spain
来源
REVISTA CLINICA ESPANOLA | 2006年 / 206卷 / 11期
关键词
risk factors; prevalence; cardiovascular prevention; antiretroviral therapy; HIV;
D O I
10.1157/13096303
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction. To determine the prevalence of cardiovascular risk factors in human immunodeficiency virus (HIV)-infected patients. Patients and method. A cross-sectional study was performed with HIV-infected patients aged 20 or over managed at the outpatient Infectious Disease Unit during 2003. Clinical and epidemiological characteristics of HIV infection and cardiovascular risk factors were evaluated. Results. The final 760 patients included in the study had a mean of 1.5 cardiovascular risk factors, with smoking being the most prevalent (66.8%; CI 95%: 63.4-70.2). The cardiovascular risk factor of age and gender was present in 26.4% (CI 95% 23.3-29.7) of patients and family history of premature coronary heart disease in 14.3% (CI 95% 11.8-16.9). The prevalence of hypertension and diabetes mellitus was 13.2% (CI 95%: 10.8-15.8) and 4.3% (CI 95%: 3.0-6.0), respectively. High density lipoprotein (HDL) cholesterol concentration under 40 mg/dl was found in 29.3% (CI 95% 26.1-32.7) and above 60 mg/dI in 16.3% (CI 95% 13.8-19.1). Twenty-five patients (3.3%; CI 95% 2.1-4.8) had suffered overt cardiovascular disease. Conclusion. Smoking and HDL cholesterol were the main cardiovascular risk factors in this HIV-infected cohort.
引用
收藏
页码:556 / 559
页数:4
相关论文
共 10 条
[1]   High-density lipoprotein concentrations relate to the clinical course of HIV viral load in patients undergoing antiretroviral therapy [J].
Alonsa-Villaverde, C ;
Segues, T ;
Coll-Crespo, B ;
Pérez-Bernalte, R ;
Rabassa, A ;
Gomila, M ;
Parra, S ;
Gozález-Estebana, AA ;
Jiménez-Expósito, J ;
Masana, L .
AIDS, 2003, 17 (08) :1173-1178
[2]  
[Anonymous], 1992, MMWR-MORBID MORTAL W, V41, P1
[3]   Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects [J].
Bergersen, BM ;
Sandvik, L ;
Bruun, JN ;
Tonstad, S .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (08) :625-630
[4]  
Carratalá FR, 2005, REV ESP CARDIOL, V58, P1411, DOI 10.1016/S1885-5857(06)60748-2
[5]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[6]   Combination antiretroviral therapy and the risk of myocardial infarction [J].
Friis-Moller, N ;
Sabin, CA ;
Weber, R ;
Monforte, AD ;
El-Sadr, WM ;
Reiss, P ;
Thiébaut, R ;
Morfeldt, L ;
De Wit, S ;
Pradier, C ;
Calvo, G ;
Law, MG ;
Kirk, O ;
Phillips, AN ;
Lundgren, JD ;
Lundgren, JD ;
Weber, R ;
Monteforte, AD ;
Bartsch, G ;
Reiss, P ;
Dabis, F ;
Morfeldt, L ;
De Wit, S ;
Pradier, C ;
Calvo, G ;
Law, MG ;
Kirk, O ;
Phillips, AN ;
Houyez, F ;
Loeliger, E ;
Tressler, R ;
Weller, I ;
Friis-Moller, N ;
Sabin, CA ;
Sjol, A ;
Lundgren, JD ;
Sawitz, A ;
Rickenbach, M ;
Pezzotti, P ;
Krum, E ;
Meester, R ;
Lavignolle, V ;
Sundström, A ;
Poll, B ;
Fontas, E ;
Torres, F ;
Petoumenos, K ;
Kjær, J ;
Hammer, S ;
Neaton, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :1993-2003
[7]   Cardiovascular disease risk factors in HIV patients -: association with antiretroviral therapy.: Results from the DAD study [J].
Friis-Moller, N ;
Weber, R ;
Reiss, P ;
Thiébaut, R ;
Kirk, O ;
Monforte, AD ;
Pradier, C ;
Morfeldt, L ;
Mateu, S ;
Law, M ;
El-Sadr, W ;
De Wit, S ;
Sabin, CA ;
Phillips, AN ;
Lundgren, JD .
AIDS, 2003, 17 (08) :1179-1193
[8]  
Medrano MJ, 2005, MED CLIN-BARCELONA, V124, P606
[9]   Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population [J].
Savès, M ;
Chêne, G ;
Ducimetière, P ;
Leport, C ;
Le Moal, G ;
Amouyel, P ;
Arveiler, D ;
Ruidavets, JB ;
Reynes, J ;
Bingham, A ;
Raffi, F .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (02) :292-298
[10]   Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population [J].
Smith, CJ ;
Levy, I ;
Sabin, CA ;
Kaya, E ;
Johnson, MA ;
Lipman, MCI .
HIV MEDICINE, 2004, 5 (02) :88-92